Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 9, 2008, Pages 1452-1460

  Valentim, Joice ^a   Passos, Vanessa ^b   Mataveli, Fabio ^c   Calabró, Alessandra ^d,e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NOVARTIS PHARMA AG   (Switzerland)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Novartis Biociências SA   (Brazil)

^e NONE   (Brazil)

Author keywords

Acromegaly; Cost effectiveness; Lanreotide; Octreotide; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYCLOPEPTIDE; DRUG DERIVATIVE; OCTREOTIDE; SOMATOSTATIN;

ACROMEGALY; ARTICLE; BRAZIL; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; PRACTICE GUIDELINE; SENSITIVITY AND SPECIFICITY;

ACROMEGALY; ANTINEOPLASTIC AGENTS, HORMONAL; BRAZIL; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; PRACTICE GUIDELINES AS TOPIC; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN;

EID: 60149085878     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000900008     Document Type: Article

References (26)

1. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, et al. American Association of Clinical Endocrinologists Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly, Endocrine Practic. 2004;10(3).
2. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in Newcastle region. Clin Endocrinol (Oxf). 1980;12:71-9.
3. Etxabe J, Gaztambide P, Latorre P, Vasquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest, 1993;16:181-7.
4. Donangelo I, Une K, Gadelha M. Diagnóstico e treatmento de acromegalia no Brasil. Arq Bras Endocrinol Metab. 2003;47(4).
5. Bengtsson B-A, Edén S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955-1984. Acta Med Scand. 1988;223:327-35.
6. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S et al. Outcome of trans-sphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf). 1996;45:407-13.
7. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992;21:669-92.
8. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005;152: 379-87.
9. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly:a consensus statement. J Clin Endocrinol Metab. 2000;85:526-9.
10. Growth Hormone Research Society, Pituitary Society. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a Joint Consensus Conference of The Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab. 2004;89:3099-102.
11. Boeving A, Borba LA, Rodrigues AM, Orichowski EB, Paz Filho GJ, Santos CM, Boguszewski CL. Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis. Arq Bras Endocrinol Metab. 2006;50(5)884-92.
12. Brasil, Ministério da Saúde, Secretaria de Assistência à Saúde. Protocolo Clínico e Diretrizes Terapêuticas para Acromegalia - octreotida, lanreotida, bromocriptina e cabergolina , Portaria no 471, de 24 de junho de 2002.
13. Moore D, Meads C, Roberts, L, Song, F. The effectiveness and cost-effectiveness of somatostatin analogues in the treatment of acromegaly, Department of Public Health, University of Birmingham. 2002.
14. King Jr. JT, Justice A, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis, J Clin Endocrinol Metab. 1997;82(11)3625-32.
15. Jaffe CA. Reevaluation of conventional pituitary irradiation in the therapy of acromegaly. Pituitary. 1999;2:55-62.
16. Jenkins PG, Elliott EL, Carson MN, Bates PR. Use of a national database to explore the effects of pituitary irraditation on serum growth hormone and IGF-1 in acromegaly. J endocrinol. 1999;163 Suppl:OCA.
17. Chanson P. Emerging drugs for acromegaly Expert Opin. Emerging Drugs. 2008;13(2):273-93.
18. Freda PU, Katznelson L, Lely AT vd, Reyes, CM, Zhao S, Rabinowitz, D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8) 4465-73.
19. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: effi cacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61(2):209-15.
20. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 1998;83:2646-52.
21. Datasus. Sistema de Informações de Mortalidade (SIM), Available at: 〈http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sim/cnv/obtuf. def〉. [Accessed: 15 october 2007].
22. Brasil. Diário Ofi cial da União, Seção 3, Comunicado no 7, 11 de junho de 2007.
23. Datasus. Sistema de Informações Ambulatoriais (SIA). Available at: 〈http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sia/cnv/pauf. def〉. [Accessed: 15 october 2007].
24. Hoomans T, Evers SMAA, Ament AJHA, Hubben MWA, van der Weijden T, Grimshaw JM, et al. The methodological quality of economic evaluations of guideline implementation into clinical practice: a systematic review of empiric studies. Value Health. 2007;10(4)305-16.
25. Melmed S. Acromegaly, N Engl J Med. 2006;355:2558-73.
26. Bloom B. Use of Formal Benefi t/Cost Evaluations in Health System Decision Making, Am J Manag Care. 2004;10:329-35.